On October 24, 2025 ChemDiv reported the extension of its discovery and early development partnership with Mondego Bio to advance the company’s best-in-class immuno-oncology program targeting PTPN2. The announcement follows Mondego Bio’s successful Series A financing led by Biovance Capital with participation from OrbiMed Advisors and Torrey Pines Investment, underscoring strong momentum behind Mondego’s strategy.
ChemDiv previously supported the accelerated discovery of a drug candidate by Eilean Therapeutics LLC in the U.S., which preceded the establishment of
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Mondego Bio in Portugal in 2025. Leveraging rational drug design across reversible, covalent, and allosteric inhibitors, the collaboration established a differentiated selectivity profile that delivers high oral bioavailability, robust in vivo efficacy, and strong safety and tolerability—hallmarks of potentially best-in-class cancer therapeutics.
Medicinal chemistry and scale-up were led by ChemDiv’s group in Germany, while pharmacology and translational biology were supported by ChemDiv facilities in the U.S. and Portugal. Together, these efforts advanced Mondego’s pre-IND program, supported by its European venture capital–backed launch.
Looking ahead, ChemDiv will continue to provide:
Medicinal chemistry and discovery biology for backup series,
CMC process research and large-scale manufacturing of the lead candidate for non-GLP and GLP animal studies,
Computational and wet-lab pharmacology to accelerate clinical readiness.
These efforts build on ChemDiv’s deep expertise in designing selective kinase and phosphatase inhibitors, leveraging its extensive kinase and phosphatase chemical libraries, and applying parallel lead optimization supported by AI/ML-enabled rational design, ADME/DMPK, and translational capabilities.
"We’re moving fast with Mondego to translate PTPN2 biology into medicines," said Ilya Baimetov, COO and Head of Digital Platforms at ChemDiv.
"By combining our advanced rational design, medchem horsepower, and focused tool libraries with Mondego’s cutting-edge immuno-oncology platform, we are advancing the next generation of phosphatase inhibitors with best-in-class potential."
(Press release, ChemDiv, OCT 24, 2025, View Source [SID1234656993])